Palliative effect of I-MIBG in relapsed neuroblastoma after autologous peripheral blood stem cell transplantation

Neuroblastoma accounts for 8-10% of all childhood malignancies. The prognosis of neuroblastoma is highly variable depending on the age at diagnosis, stage of the disease, and tumor biology. High risk is defined as neuroblastoma occurring in children over 1 year of age with an amplification of the MYCN oncogene or distant metastasis 1) . Despite recent improvements in outcome with intensification of therapy for metastatic neuroblastoma, the long-term prognosis of advanced neuroblastoma remains poor with current survival probability of less than 40% 1, 2) . Multiply relapsed patients have been treated with 131 IMIBG over the last 2 decades for palliative effects 3, 4) . We report the palliative effects of 131 I-MIBG in three cases of relapsed neuroblastoma after autologous peripheral blood stem cell transplantation.